Strategic Acquisition StemoniX assets were acquired by AxoSim in 2023, signaling a consolidation in CNS organoid platforms. For sales outreach, target customers may be evaluating integrated neurodiscovery solutions from a single provider, presenting an upsell path from Vyant Bio StemoniX relationships to AxoSim's expanded microBrain platform.

High Value Platform microBrain organoids offer physiologically relevant human iPSC-derived CNS screening with 3D networks, ideal for high-throughput neurotoxicology, neuromodulation, and drug discovery. Position as a scalable, reproducible platform that can shorten preclinical timelines for pharma and biotech customers seeking CNS safety and efficacy data.

Strategic Hires Recent leadership additions in sales and marketing and board-level appointments indicate a push to scale commercial efforts and governance. Leverage this as a signal for readiness to engage with larger pharma accounts and to propose enterprise-wide neurodiscovery partnerships or custom service agreements.

Market Fit Revenue range and comparable peers suggest mid-market focus with growth potential in biotech labs and CROs seeking advanced CNS screening. Target mid-sized biotech companies and contract research organizations that require human-relevant CNS models to differentiate their drug discovery pipelines.

Expansion Opportunities The combination of AxoSim’s platform and Vyant Bio StemoniX assets creates potential for bundled offerings, services, and tool integrations. Explore opportunities for integrated assays, data analytics collaborations, and turnkey screening packages to accelerate customers’ neurodrug development and safety assessment.